Data Supplement

• Supplemental Data -

  Supplemental Methods.
  

  Supplemental Table 1. Mean plasma concentration of BI 685509 after oral administration of 5.83 mg/kg BI 685509 in B6.V-Lep-ob/J mice.
  

  Supplemental Table 2. Mean plasma concentration of BI 685509 afteri.v. 1 mg/kg and oral 3 mg/kg administration of BI 685509 in wistar han rats.
  

  Supplemental Table 3.
  

  Supplemental Fig. 1. General study protocol for UUO and ZSF1 studies indicating relative time for procedures during the course of the 7d or 10wk studies, respectively.
  

  Supplemental Fig. 2. Mean plasma concentrations of BI 685509 (A) and enalaprilat (B) in ZSF1 rats.
  

  Supplemental Fig. 3. Effects of BI 685509 and enalapril on body weight and feeding parameters.
  

  Supplemental Fig. 4. Scatterplot of changes of fold-change between BI 685509 and Vehicle-treated groups in UUO model, comparing 10 mg/kg and 30 mg/kg doses.
  

  Supplemental Fig. 5. Boxplots of gene expression across groups for urate transporters, Slc14a1, Slc14a2, Upk3a, and Aqp3.
  

  Supplemental Fig. 6. Heatmap of extracellular-matrix-associated genes upregulated in UUO model and downregulated in groups treated with 10 mg/kg and 30 mg/kg doses of BI 685509.
  

  Supplemental Fig. 7. Heatmap of podocyte-associated genes decreased in UUO model and upregulated in groups treated with 10 mg/kg and 30 mg/kg doses of BI 685509.
  

  Supplemental Fig. 8. Scatterplot of the relationship between Col1a1 expression by RNAseq and Sirius Red Morphometry.